INDIANAPOLIS, Aug. 25, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) today announced that the U.S. District Court
for the Southern District of Indiana has ruled in the company's favor
regarding infringement of the vitamin regimen patent for
Alimta® (pemetrexed for injection).
In the case of Eli Lilly and Company v. Teva Parenteral
Medicines, Inc., et al., the court ruled that the vitamin
regimen patent would be infringed by the generic challengers'
proposed products. The patent provides intellectual property
protection for Alimta until May 2022. In March 2014, the court previously upheld the
validity of the vitamin regimen patent. The Alimta compound patent
remains in force through early 2017.
"We are pleased with today's District Court ruling on Alimta
finding the vitamin regimen patent would be infringed," said
Michael J. Harrington, senior vice
president and general counsel for Lilly. "The significant
scientific research that Lilly performed in support of the vitamin
regimen patent deserves intellectual property protection. We
continue to emphasize that protection of intellectual property
rights is extremely important to the biopharmaceutical industry and
the patients we serve. These rights help support the development of
the next generation of innovative medicines to treat unmet medical
needs."
About Eli Lilly and Company
Lilly is a
global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than
a century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels.
C-LLY
This release contains forward-looking statements regarding the
U.S. Alimta patent litigation. These statements are based on
management's current expectations but actual results may differ
materially. There can be no assurance that the company will
prevail in any appeal. Also, the company cannot predict
whether generic pemetrexed will be marketed prior to the expiration
of the vitamin regimen patent. Other risk factors that may
affect the company's results can be found in the company's latest
Forms 10-K and 10-Q filed with the U.S. Securities and Exchange
Commission.
________________________
Alimta® (pemetrexed, Lilly)
Refer
to:
|
Carla L. Cox;
coxcl@lilly.com; (317) 473-4368 (Media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; (317) 655-6874
(Investors)
|
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/us-district-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patent-300133168.html
SOURCE Eli Lilly and Company